ADMA Biologics Stock (NASDAQ:ADMA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$22.62

52W Range

$3.60 - $23.63

50D Avg

$18.12

200D Avg

$11.47

Market Cap

$5.31B

Avg Vol (3M)

$5.27M

Beta

0.65

Div Yield

-

ADMA Company Profile


ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

624

IPO Date

Oct 17, 2013

Website

ADMA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Plasma Collection Centers Segment$8.12M--
ADMA BioManufacturing Segment$161.16M--
Product Revenue-$153.94M$80.80M
License Revenue-$142.83K$142.83K

Fiscal year ends in Dec 23 | Currency in USD

ADMA Financial Summary


Dec 23Dec 22Dec 21
Revenue$258.21M$154.08M$80.94M
Operating Income$21.63M$-39.37M$-58.37M
Net Income$-28.24M$-85.18M$-84.45M
EBITDA$21.63M$-39.24M$-57.88M
Basic EPS-$-0.43$-0.61
Diluted EPS-$-0.43$-0.61

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 07, 24 | 10:12 PM
Q2 24Aug 08, 24 | 11:56 PM
Q1 24May 09, 24 | 11:11 PM

Peer Comparison


TickerCompany
PLRXPliant Therapeutics, Inc.
SANASana Biotechnology, Inc.
BCRXBioCryst Pharmaceuticals, Inc.
XFORX4 Pharmaceuticals, Inc.
AKBAAkebia Therapeutics, Inc.
ATRAAtara Biotherapeutics, Inc.
FATEFate Therapeutics, Inc.
RCUSArcus Biosciences, Inc.
STOKStoke Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
CRBUCaribou Biosciences, Inc.
ANTXAN2 Therapeutics, Inc.
ACLXArcellx, Inc.
TFFPTFF Pharmaceuticals, Inc.
ETNB89bio, Inc.
VXRTVaxart, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
CDTXCidara Therapeutics, Inc.
INMBINmune Bio, Inc.
MDGLMadrigal Pharmaceuticals, Inc.